Negative trials in ovarian cancer: is there such a thing as too much optimism?

Ecancermedicalscience

Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, USA; Department of Public Health and Preventive Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon, USA; Center for Health Care Ethics, Oregon Health and Science University, Portland, Oregon 97239, USA.

Published: September 2016

Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study. Using these examples, we point out the discrepancies and the risks of concluding optimistically based on statistical significance when the actual benefit is minimal. We also appeal against conducting large phase 3 trials that require significant resources without good phase 2 evidence for doing so.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990052PMC
http://dx.doi.org/10.3332/ecancer.2016.ed58DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
8
phase study
8
negative trials
4
trials ovarian
4
cancer thing
4
thing optimism?
4
optimism? clinical
4
clinical trials
4
trials novel
4
novel agents
4

Similar Publications

Rare malignant ovarian tumors: a review.

Jpn J Clin Oncol

January 2025

Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known for its aggressive behavior.

View Article and Find Full Text PDF

Introduction Evidence suggests inflammation plays a key role in the development of ovarian malignancy. This study investigated the relationship between the C-reactive protein (CRP) to serum albumin (Alb) ratio and clinicopathological parameters in ovarian cancer patients. The goal was to determine if this readily measurable inflammatory marker could provide insights into disease severity.

View Article and Find Full Text PDF

Autoimmune cerebellar ataxia (ACA) is a cerebellar syndrome induced by autoimmune reactions and its onset is induced by malignant tumors, prodromic infection, and gluten allergy. Its clinical symptoms include gait disorder, limb ataxia, dysarthria, and dysphagia. According to , the diagnosis of ACA is based on the following points: 1.

View Article and Find Full Text PDF

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

Front Oncol

January 2025

Laboratorio de Farmacogenética, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.

Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow.

View Article and Find Full Text PDF

Background: Immune cells within tumor tissues play important roles in remodeling the tumor microenvironment, thus affecting tumor progression and the therapeutic response. The current study was designed to identify key markers of plasma cells and explore their role in high-grade serous ovarian cancer (HGSOC).

Methods: We utilized single-cell sequencing data from the Gene Expression Omnibus (GEO) database to identify key immune cell types within HGSOC tissues and to extract related markers via the Seurat package.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!